Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05578846 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT05578846 is a Phase 1 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 42 participants.
The verdict
NCT05578846, a Phase 1 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study will assess the Bioequivalence between 180 mg and 60 mg ALXN2050 Tablets and the Effect of Food on ALXN2050 Pharmacokinetics.
Interventions
- DRUG Treatment A
- DRUG Treatment B
- DRUG Treatment C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-10-13 |
| Est. Completion | 2023-01-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05578846
The ClinicalTrials.gov registry entry for NCT05578846 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Treatment A is the first listed.
NCT05578846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05578846 about?
NCT05578846 is a clinical study titled "Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics". This study will assess the Bioequivalence between 180 mg and 60 mg ALXN2050 Tablets and the Effect of Food on ALXN2050 Pharmacokinetics.
What is the current status of trial NCT05578846?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2022-10-13. Estimated completion is 2023-01-05.
What interventions are being tested in trial NCT05578846?
The interventions under investigation include: Treatment A (DRUG), Treatment B (DRUG), Treatment C (DRUG).
Who is sponsoring clinical trial NCT05578846?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.